)

AbCellera Biologics (ABCL) investor relations material
AbCellera Biologics Wells Fargo 20th Annual Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Company evolution and strategic shift
Transitioned from a partnership and royalty-based model to developing an internal pipeline of therapeutic antibodies, leveraging advanced technology for difficult targets like GPCRs and ion channels.
Built integrated capabilities from target discovery to GMP manufacturing, with significant infrastructure and talent investments, supported by government funding.
Successfully brought first two proprietary antibodies, ABCL635 and ABCL575, into clinical trials in 2024, marking a major operational milestone.
Demonstrated strong execution by submitting two clinical trial authorizations (CTAs) in Q2 2024 and initiating patient dosing.
Maintains selective strategic partnerships for validation and portfolio management, while focusing on internal program advancement.
Pipeline highlights and clinical development
ABCL635 targets NK3R for non-hormonal treatment of hot flashes in postmenopausal women, addressing a $2 billion market with unmet need.
Phase one design includes biomarker-driven proof of concept, with efficacy and safety readouts expected by mid-2026.
ABCL575, an OX40 ligand antibody, aims for longer dosing intervals and is positioned as a potential second-line therapy in atopic dermatitis and other inflammatory conditions.
Additional proprietary program, ABCL688, is scheduled to enter the clinic in mid-2026, with a focus on complex membrane protein targets and similar market potential.
Plans to advance two new clinical candidates per year, with portfolio management decisions based on clinical data and market dynamics.
Capital allocation and business model
Holds over $500 million in cash and nearly $200 million in additional government funding, providing at least three years of operational runway.
Capital allocation strategy prioritizes advancing internal programs through phase one, with asset-by-asset decisions for later-stage development or partnerships.
Intends to partner or out-license certain assets, such as ABCL575, to optimize value and manage portfolio risk.
Continues to selectively sign new partnership and royalty deals, maintaining relationships with major pharma companies for both validation and future collaboration.
Royalty portfolio and partnered programs remain a source of potential upside, though not the primary growth driver.
Next AbCellera Biologics earnings date

Next AbCellera Biologics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage